Medicamen Biotech Limited

BSE: 531146 NSE: MEDICAMEQ
Medicamen Biotech Limited - pharma in New Delhi, Delhi, India. FY 2026 financials and compliance.
CIN L74899DL1993PLC056594 Incorporated 22 December 1993 ROC Delhi HQ New Delhi, Delhi, India
Active Listed - NSE: MEDICAMEQ · BSE: 531146 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹197.77 Cr
▲ 21.67% YoY
Computed EBITDA · FY 2026
₹22.7 Cr
▲ 12.92% YoY
Net profit · FY 2026
₹9.8 Cr
▲ 49.43% YoY
Authorised capital
₹15 Cr
Registered with MCA
Paid-up capital
₹13.56 Cr
Issued & subscribed
Open charges
₹66.43 Cr
Satisfied ₹52.09 Cr
Company age
33 yrs
Est. 1993
Employees · EPFO
314
Latest available

About Medicamen Biotech Limited

Data last updated: 14 July 2026

Medicamen Biotech Limited is a public limited company based in New Delhi, Delhi, India, a subsidiary of Shivalik Rasayan Limited. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 22 December 1993, the company has been in operation for over 33 years.

Registered with ROC Delhi under CIN L74899DL1993PLC056594. Listed on BSE: 531146 and NSE: MEDICAMEQ.

Capital: an authorised share capital of ₹15 Cr and a paid-up capital of ₹13.56 Cr. It is led by directors including Vimal Kumar Shrawat and Sumita Dwivedi.

Last AGM: 26 September 2025. Financial statements filed for year ended 31 March 2025. Office: 1506 Chiranjiv Tower 43 Nehru Place, New Delhi, Delhi, India – 110019.

As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹197.77 Cr, a growth of 21.67% compared to the previous year. The net worth stands at ₹275.55 Cr (up 29.5% YoY). Total assets are valued at ₹371.99 Cr (up 25.3% YoY).

The company has a workforce of approximately 314 employees as per the latest available data. It operates as a subsidiary of Shivalik Rasayan Limited. Its group structure includes 1 subsidiary.

The company is associated with 1 brand - Medicamen. As per MCA filings, the company has open charges of ₹66.43 Cr and satisfied charges of ₹52.09 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website medicamen.com.

Company Details of Medicamen Biotech Limited
CIN L74899DL1993PLC056594
Registration Number 056594
Incorporation Date 22 December 1993
ROC Delhi
Listing Status Listed (BSE: 531146, NSE: MEDICAMEQ)
Company Status Active
Date of Last AGM 26 September 2025
Date of Balance Sheet 31 March 2025
Parent Company Shivalik Rasayan Limited
Compliance Status Active Compliant
Key People
Ashwani Kumar Sharma Whole-Time Director Vimal Kumar Shrawat Director Sumita Dwivedi Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    medicamen.com
  • Social Media
  • Registered Address
    1506 Chiranjiv Tower 43 Nehru Place, New Delhi, Delhi, India – 110019
  • Industry
    Pharma, Drug Formulation & Development
Company report
Medicamen Biotech Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Medicamen Biotech Limited report

Financials, compliance, directors, charges, ownership and filings for Medicamen Biotech Limited in one report.

10-year financials Directors & ownership Charges & compliance

Associated Brands with Medicamen Biotech Limited

Medicamen Biotech Limited operates one associated brand: Medicamen. These brands represent Medicamen Biotech Limited's diversified market presence and brand portfolio.

Brand Description Website
Medicamen
Manufacturer of tablets, capsules, syrups, ointments and ORS medicamen.com

Competitors & Alternatives of Medicamen Biotech Limited

Brands and companies operating in the same space as Medicamen Biotech Limited include Jubilant Life Sciences, Akums, Nectar Lifesciences and 7 more.

Competitor Description Location Founded
Jubilant Life Sciences Jubilant Life Sciences Company offering a suite of R&D and manufacturing services for small molecules and generics Noida, India, India 1978
Akums Akums CDMO focusing on spectrum of dosage forms and therapeutic segments Delhi, India, India 2004
Nectar Lifesciences Nectar Lifesciences Cephalosporin APIs and generic formulations are manufactured. Chandigarh, India, India 1995
Windlas Windlas Biopharma regulatory affairs, quality control, and strategy services are provided. Gurugram, India, India 2001
Unither Unither Contract development and manufacturing organization for proprietary and generic drugs Paris, France, France 1993
Recipharm Recipharm Pharmaceutical development and manufacturing services are offered contractually. Jordbro, Sweden, Sweden 1995
CoreRx CoreRx CDMO with a focus on early phase drug product development Clearwater, United States, United States 2006
Aenova Group Aenova Group CDMO services for pharmaceuticals, medical devices, and nutraceuticals are provided. Starnberg, Germany, Germany 2008
Zambon Pharma Zambon Pharma APIs and finished drugs are developed and manufactured in pharmaceuticals. Bresso, Italy, Italy 1906
Leukocare Leukocare Proprietary stabilizing solutions for biologics formulations are developed. Munich, Germany, Germany 2003

Business Activity of Medicamen Biotech Limited

Medicamen Biotech Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Medicamen Biotech Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Medicamen Biotech Limited

Medicamen Biotech Limited is audited by M/s Rai Qimat & Associates (ICAI peer reviewed, certificate valid till 2026-11-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
M/s Rai Qimat & Associates (ICAI peer reviewed, certificate valid till 2026-11-30) FY 2026 Declaration of unmodified opinion

Board of Directors of Medicamen Biotech Limited

Medicamen Biotech Limited is currently managed by 10 directors, with 30 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Vimal Kumar Shrawat
Also directs: Shivalik Rasayan Limited, Chem Pharma Healthcare Private Limited
Director 11 Feb 2019 7 Years 7 Months Current
Sumita Dwivedi
Also directs: Shivalik Rasayan Limited, Skyforge System Solutions Llp
Director 13 Nov 2018 7 Years 10 Months Current
Sangeeta Bishnoi
Also directs: Shivalik Rasayan Limited
Director 11 Feb 2019 7 Years 7 Months Current
Ravi Kumar Bansal
Also directs: Shivalik Rasayan Limited
Director 30 May 2019 7 Years 3 Months Current
Sanjay Bansal
Also directs: J B Spintex Private Limited, Genius Constructions Private Limited, Versatile Land Base Private Limited and 1 more
Director 27 Feb 2016 10 Years 6 Months Current
Ashwani Kumar Sharma
Also directs: Shivalik Rasayan Limited, Medicamen Life Sciences Private Limited, Growel Remedies Limited
Whole-Time Director 31 Dec 2015 10 Years 8 Months Current
Showing 6 of 10 current directors. View all directors

Financials of Medicamen Biotech Limited FY 2026 filings available

Medicamen Biotech Limited reported revenue of ₹197.77 Cr (up 21.67% YoY) for FY 2026.

Revenue · FY 2026
₹197.77 Cr ▲ 21.67%
Profit · FY 2026
₹9.8 Cr ▲ 49.43%
Computed EBITDA · FY 2026
₹22.7 Cr ▲ 12.92%
Revenue₹ Cr · Consolidated0100200FY 2022: ₹115 Cr115FY 2022FY 2023: ₹141 Cr · +22% YoY141+22%FY 2023FY 2024: ₹179 Cr · +27.3% YoY179+27.3%FY 2024FY 2025: ₹163 Cr · -9.3% YoY163-9.3%FY 2025FY 2026: ₹198 Cr · +21.7% YoY198+21.7%FY 2026
Net Profit₹ Cr · Consolidated051015FY 2022: ₹15 Cr14.9FY 2022FY 2023: ₹15 Cr · -1.1% YoY14.7-1.1%FY 2023FY 2024: ₹9 Cr · -35.5% YoY9.5-35.5%FY 2024FY 2025: ₹7 Cr · -30.9% YoY6.6-30.9%FY 2025FY 2026: ₹10 Cr · +49.4% YoY9.8+49.4%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year0255075Q1'25: ₹43 Cr · +2.6% YoY43+2.6%Q1'25Q2'25: ₹45 Cr · +2.8% YoY44.7+2.8%Q2'25Q3'25: ₹45 Cr · -2.9% YoY45.1-2.9%Q3'25Q4'25: ₹30 Cr · -37.4% YoY29.6-37.4%Q4'25Q1'26: ₹43 Cr · +0% YoY43+0%Q1'26Q2'26: ₹47 Cr · +5.4% YoY47.2+5.4%Q2'26Q3'26: ₹47 Cr · +3.9% YoY46.9+3.9%Q3'26Q4'26: ₹61 Cr · +104.8% YoY60.6+104.8%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Revenue from Operations ₹197.77 Cr ₹162.55 Cr ₹179.31 Cr ₹140.87 Cr ₹115.45 Cr
Other Income ₹3.11 Cr ₹6.24 Cr ₹2.33 Cr ₹2.46 Cr ₹1.72 Cr
Total Income ₹200.88 Cr ₹168.79 Cr ₹181.63 Cr ₹143.33 Cr ₹117.17 Cr
Cost of Materials Consumed ₹94.35 Cr ₹90.65 Cr ₹104.7 Cr ₹81.8 Cr ₹55.69 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹7.42 Cr -₹6.03 Cr -₹12.1 Cr -₹9.71 Cr -₹3.34 Cr
Employee Benefit Expense ₹34.69 Cr ₹31.87 Cr ₹30.07 Cr ₹20.44 Cr ₹14.5 Cr
Finance Costs ₹3.5 Cr ₹3.16 Cr ₹4.4 Cr ₹2.92 Cr ₹1.4 Cr
Depreciation & Amortisation ₹7.22 Cr ₹7.07 Cr ₹7.09 Cr ₹6.37 Cr ₹5.77 Cr
Other Expenses ₹41.72 Cr ₹32.2 Cr ₹34.4 Cr ₹24.46 Cr ₹25.04 Cr
Total Expenses ₹188.9 Cr ₹158.91 Cr ₹168.56 Cr ₹126.28 Cr ₹99.07 Cr
Profit Before Exceptional Items & Tax ₹11.98 Cr ₹9.88 Cr ₹13.08 Cr ₹17.05 Cr ₹18.09 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹11.98 Cr ₹9.88 Cr ₹13.08 Cr ₹17.05 Cr ₹18.09 Cr
Total Tax Expense ₹2.19 Cr ₹3.32 Cr ₹3.58 Cr ₹2.32 Cr ₹3.2 Cr
Net Profit ₹9.8 Cr ₹6.56 Cr ₹9.49 Cr ₹14.73 Cr ₹14.9 Cr
  attributable to Owners ₹9.64 Cr ₹7.11 Cr ₹10.93 Cr ₹14.84 Cr ₹0
  attributable to NCI ₹15.51 Lakh -₹55.25 Lakh -₹1.44 Cr -₹11.56 Lakh ₹0
Other Comprehensive Income ₹0 ₹0 ₹0 ₹0 ₹0
Total Comprehensive Income ₹9.8 Cr ₹6.56 Cr ₹9.49 Cr ₹14.73 Cr ₹14.9 Cr
EBITDA (computed) ₹22.7 Cr ₹20.1 Cr ₹24.57 Cr ₹26.33 Cr ₹25.27 Cr
Basic EPS ₹7.22 ₹5.16 ₹7.50 ₹11.82 ₹12.19
Diluted EPS ₹7.22 ₹5.16 ₹7.50 ₹11.82 ₹12.19
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹371.99 Cr ₹296.88 Cr ₹294.52 Cr ₹278.52 Cr
Non-current Assets ₹148.25 Cr ₹132.33 Cr ₹134.93 Cr ₹115.15 Cr
Current Assets ₹223.73 Cr ₹164.55 Cr ₹159.59 Cr ₹163.36 Cr
Property, Plant & Equipment ₹84.09 Cr ₹86.12 Cr ₹90.95 Cr ₹91.76 Cr
Inventories ₹70.08 Cr ₹62.14 Cr ₹59.38 Cr ₹45.06 Cr
Trade Receivables ₹81.83 Cr ₹68.9 Cr ₹55.26 Cr ₹65.26 Cr
Cash & Equivalents ₹31.26 Cr ₹3.76 Cr ₹14.79 Cr ₹20.78 Cr
Equity (Net Worth) ₹275.55 Cr ₹212.78 Cr ₹200.49 Cr ₹193.41 Cr
Equity Share Capital ₹13.56 Cr ₹12.71 Cr ₹12.71 Cr ₹12.65 Cr
Borrowings (Non-current) ₹6.15 Cr ₹3.73 Cr ₹1.26 Cr ₹86.96 Lakh
Borrowings (Current) ₹41.63 Cr ₹29.52 Cr ₹29.56 Cr ₹23.31 Cr
Total Debt (computed) ₹47.78 Cr ₹33.25 Cr ₹30.82 Cr ₹24.18 Cr
Current Liabilities ₹87.92 Cr ₹78.17 Cr ₹91.03 Cr ₹82.57 Cr
Total Liabilities ₹96.44 Cr ₹84.1 Cr ₹94.04 Cr ₹85.1 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow -₹33.17 Cr -₹7.19 Cr -₹36.58 Lakh -₹6.29 Cr ₹4.11 Cr
Investing Cash Flow -₹3.04 Cr -₹1.89 Cr -₹5.56 Cr -₹5.88 Cr -₹8.47 Cr
Financing Cash Flow ₹63.72 Cr -₹1.94 Cr -₹6.48 Lakh ₹29.13 Cr ₹4.3 Cr
Capital Expenditure ₹4.78 Cr ₹2.07 Cr ₹0 ₹6.6 Cr ₹8.61 Cr
Free Cash Flow (computed) -₹37.95 Cr -₹9.27 Cr -₹36.58 Lakh -₹12.89 Cr -₹4.5 Cr
Dividends Paid ₹1.36 Cr ₹1.27 Cr ₹1.27 Cr ₹1.27 Cr ₹1.22 Cr
Net Change in Cash ₹27.5 Cr -₹11.02 Cr -₹5.99 Cr ₹16.95 Cr -₹6.58 Lakh
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹60.65 Cr ₹46.91 Cr ₹47.17 Cr ₹43.04 Cr ₹29.61 Cr ₹45.14 Cr ₹44.74 Cr ₹43.05 Cr ₹47.32 Cr ₹46.5 Cr ₹43.54 Cr ₹41.94 Cr
Other Income ₹1.74 Cr ₹53.49 Lakh ₹37.28 Lakh ₹47.03 Lakh ₹5.23 Cr ₹14.07 Lakh ₹28.96 Lakh ₹58.63 Lakh ₹56.62 Lakh ₹83.05 Lakh ₹54.98 Lakh ₹37.92 Lakh
Total Income ₹62.38 Cr ₹47.44 Cr ₹47.54 Cr ₹43.52 Cr ₹34.84 Cr ₹45.28 Cr ₹45.03 Cr ₹43.63 Cr ₹47.89 Cr ₹47.33 Cr ₹44.09 Cr ₹42.32 Cr
Cost of Materials Consumed ₹26.09 Cr ₹21.69 Cr ₹21.97 Cr ₹24.6 Cr ₹11.52 Cr ₹28.52 Cr ₹28.94 Cr ₹21.67 Cr ₹21.82 Cr ₹29.1 Cr ₹27.67 Cr ₹26.11 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹6.1 Cr ₹2.02 Cr ₹1.18 Cr -₹1.88 Cr ₹2.25 Cr -₹6.2 Cr -₹4.5 Cr ₹2.43 Cr ₹1.77 Cr -₹4.11 Cr -₹4.52 Cr -₹5.24 Cr
Employee Benefit Expense ₹9.4 Cr ₹8.37 Cr ₹8.83 Cr ₹8.09 Cr ₹8.4 Cr ₹8 Cr ₹7.63 Cr ₹7.84 Cr ₹8.39 Cr ₹8.01 Cr ₹7.1 Cr ₹6.56 Cr
Finance Costs ₹38.3 Lakh ₹97.2 Lakh ₹98.89 Lakh ₹1.15 Cr ₹64.99 Lakh ₹75.95 Lakh ₹1.04 Cr ₹70.57 Lakh ₹1.89 Cr ₹64.66 Lakh ₹90.72 Lakh ₹95.65 Lakh
Depreciation & Amortisation ₹1.73 Cr ₹1.83 Cr ₹1.86 Cr ₹1.8 Cr ₹47.89 Lakh ₹2.21 Cr ₹2.61 Cr ₹1.77 Cr ₹1.77 Cr ₹1.8 Cr ₹1.82 Cr ₹1.69 Cr
Other Expenses ₹13.61 Cr ₹10.45 Cr ₹10.03 Cr ₹7.63 Cr ₹9.06 Cr ₹8.11 Cr ₹7.35 Cr ₹7.68 Cr ₹9.58 Cr ₹8.62 Cr ₹8.65 Cr ₹7.56 Cr
Total Expenses ₹57.32 Cr ₹45.33 Cr ₹44.86 Cr ₹41.38 Cr ₹32.35 Cr ₹41.41 Cr ₹43.08 Cr ₹42.08 Cr ₹45.23 Cr ₹44.06 Cr ₹41.63 Cr ₹37.64 Cr
Profit Before Exceptional Items & Tax ₹5.06 Cr ₹2.11 Cr ₹2.68 Cr ₹2.13 Cr ₹2.49 Cr ₹3.88 Cr ₹1.96 Cr ₹1.56 Cr ₹2.66 Cr ₹3.27 Cr ₹2.46 Cr ₹4.68 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹5.06 Cr ₹2.11 Cr ₹2.68 Cr ₹2.13 Cr ₹2.49 Cr ₹3.88 Cr ₹1.96 Cr ₹1.56 Cr ₹2.66 Cr ₹3.27 Cr ₹2.46 Cr ₹4.68 Cr
Total Tax Expense ₹61.27 Lakh ₹47.62 Lakh ₹56.86 Lakh ₹53.05 Lakh ₹62.66 Lakh ₹95.49 Lakh ₹1.05 Cr ₹75.76 Lakh ₹61.52 Lakh ₹1.24 Cr ₹98.78 Lakh ₹73.63 Lakh
Net Profit ₹4.45 Cr ₹1.63 Cr ₹2.11 Cr ₹1.6 Cr ₹1.86 Cr ₹2.92 Cr ₹90.39 Lakh ₹79.87 Lakh ₹2.04 Cr ₹2.03 Cr ₹1.48 Cr ₹3.95 Cr
  attributable to Owners ₹3.86 Cr ₹2.19 Cr ₹2.67 Cr ₹2.15 Cr ₹2.42 Cr - ₹1.46 Cr ₹1.35 Cr ₹2.13 Cr ₹0 ₹1.51 Cr -
  attributable to NCI ₹58.99 Lakh -₹55.25 Lakh -₹55.25 Lakh -₹55.25 Lakh -₹55.25 Lakh - -₹55.25 Lakh -₹55.25 Lakh -₹8.74 Lakh ₹0 -₹75.25 Lakh -₹23.02 Lakh
Other Comprehensive Income ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Total Comprehensive Income ₹4.45 Cr ₹1.63 Cr ₹2.11 Cr ₹1.6 Cr ₹1.86 Cr ₹2.92 Cr ₹90.39 Lakh ₹79.87 Lakh ₹2.04 Cr ₹2.03 Cr ₹1.48 Cr ₹3.95 Cr
EBITDA (computed) ₹7.18 Cr ₹4.91 Cr ₹5.53 Cr ₹5.09 Cr ₹3.62 Cr ₹6.85 Cr ₹5.6 Cr ₹4.03 Cr ₹6.32 Cr ₹5.72 Cr ₹5.19 Cr ₹7.33 Cr
Basic EPS ₹3.28 ₹1.21 ₹1.56 ₹1.18 ₹1.47 ₹2.30 ₹0.71 ₹0.63 ₹1.61 ₹1.60 ₹1.17 ₹3.12
Diluted EPS ₹3.28 ₹1.21 ₹1.56 ₹1.18 ₹1.47 ₹2.30 ₹0.71 ₹0.63 ₹1.61 ₹1.60 ₹1.17 ₹3.12
Latest 12 quarters shown of 19 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Revenue from Operations ₹178.85 Cr ₹151.46 Cr ₹172.39 Cr ₹137.88 Cr
Other Income ₹3.1 Cr ₹6.23 Cr ₹2.3 Cr ₹2.46 Cr
Total Income ₹181.95 Cr ₹157.69 Cr ₹174.69 Cr ₹140.35 Cr
Cost of Materials Consumed ₹91.81 Cr ₹88.83 Cr ₹104.7 Cr ₹81.8 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹7.42 Cr -₹6.08 Cr -₹13.32 Cr -₹10.3 Cr
Employee Benefit Expense ₹22.79 Cr ₹21.57 Cr ₹22.12 Cr ₹18.57 Cr
Finance Costs ₹2.78 Cr ₹3.05 Cr ₹4.38 Cr ₹2.92 Cr
Depreciation & Amortisation ₹7.06 Cr ₹6.95 Cr ₹7.01 Cr ₹6.35 Cr
Other Expenses ₹38.53 Cr ₹30.58 Cr ₹32.92 Cr ₹23.66 Cr
Total Expenses ₹170.4 Cr ₹144.9 Cr ₹157.8 Cr ₹123.01 Cr
Profit Before Exceptional Items & Tax ₹11.55 Cr ₹12.78 Cr ₹16.89 Cr ₹17.33 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹11.55 Cr ₹12.78 Cr ₹16.89 Cr ₹17.33 Cr
Total Tax Expense ₹2.14 Cr ₹3.32 Cr ₹3.59 Cr ₹2.33 Cr
Net Profit ₹9.41 Cr ₹9.46 Cr ₹13.3 Cr ₹15 Cr
Other Comprehensive Income ₹0 ₹0 ₹0 ₹0
Total Comprehensive Income ₹9.41 Cr ₹9.46 Cr ₹13.3 Cr ₹15 Cr
EBITDA (computed) ₹21.39 Cr ₹22.78 Cr ₹28.27 Cr ₹26.61 Cr
Basic EPS ₹6.94 ₹7.44 ₹10.50 ₹12.04
Diluted EPS ₹6.94 ₹7.44 ₹10.50 ₹12.04
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹361.52 Cr ₹292.93 Cr ₹294.21 Cr ₹276.78 Cr
Non-current Assets ₹155.4 Cr ₹139.42 Cr ₹141.84 Cr ₹118.81 Cr
Current Assets ₹206.12 Cr ₹153.51 Cr ₹152.37 Cr ₹157.97 Cr
Property, Plant & Equipment ₹83.27 Cr ₹85.32 Cr ₹90.21 Cr ₹91.47 Cr
Inventories ₹70.08 Cr ₹62.14 Cr ₹59.33 Cr ₹45.06 Cr
Trade Receivables ₹64.91 Cr ₹58.62 Cr ₹48.29 Cr ₹60.23 Cr
Cash & Equivalents ₹31.08 Cr ₹3.58 Cr ₹14.62 Cr ₹20.44 Cr
Equity (Net Worth) ₹279.73 Cr ₹217.38 Cr ₹209.21 Cr ₹193.8 Cr
Equity Share Capital ₹13.56 Cr ₹12.71 Cr ₹12.71 Cr ₹12.65 Cr
Borrowings (Non-current) ₹77.71 Lakh ₹76.39 Lakh ₹95.06 Lakh ₹86.96 Lakh
Borrowings (Current) ₹36.16 Cr ₹26.45 Cr ₹28.64 Cr ₹23.31 Cr
Total Debt (computed) ₹36.93 Cr ₹27.22 Cr ₹29.59 Cr ₹24.18 Cr
Current Liabilities ₹78.65 Cr ₹72.58 Cr ₹82.3 Cr ₹80.46 Cr
Total Liabilities ₹81.79 Cr ₹75.55 Cr ₹85.01 Cr ₹82.99 Cr
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Operating Cash Flow -₹29.26 Cr -₹2.01 Cr -₹24.6 Lakh -₹3.51 Cr
Investing Cash Flow -₹2.85 Cr -₹1.72 Cr -₹8.71 Cr -₹7.53 Cr
Financing Cash Flow ₹59.61 Cr -₹7.31 Cr ₹3.14 Cr ₹27.67 Cr
Capital Expenditure ₹0 ₹1.91 Cr ₹0 ₹6.23 Cr
Free Cash Flow (computed) -₹29.26 Cr -₹3.92 Cr -₹24.6 Lakh -₹9.75 Cr
Dividends Paid ₹1.36 Cr ₹1.27 Cr ₹1.27 Cr ₹1.27 Cr
Net Change in Cash ₹27.5 Cr -₹11.04 Cr -₹5.82 Cr ₹16.63 Cr
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹54.68 Cr ₹43.49 Cr ₹42.23 Cr ₹38.45 Cr ₹26 Cr ₹41.14 Cr ₹42.84 Cr ₹41.48 Cr ₹45.01 Cr ₹44.2 Cr ₹42.67 Cr ₹40.5 Cr
Other Income ₹1.73 Cr ₹53.49 Lakh ₹37.28 Lakh ₹47.03 Lakh ₹5.22 Cr ₹14.08 Lakh ₹28.96 Lakh ₹57.52 Lakh ₹54.31 Lakh ₹83.05 Lakh ₹54.98 Lakh ₹37.92 Lakh
Total Income ₹56.41 Cr ₹44.03 Cr ₹42.6 Cr ₹38.92 Cr ₹31.21 Cr ₹41.28 Cr ₹43.13 Cr ₹42.06 Cr ₹45.55 Cr ₹45.04 Cr ₹43.22 Cr ₹40.88 Cr
Cost of Materials Consumed ₹25.43 Cr ₹21.25 Cr ₹21.26 Cr ₹23.88 Cr ₹10.91 Cr ₹27.88 Cr ₹28.62 Cr ₹21.42 Cr ₹22.65 Cr ₹28.72 Cr ₹27.51 Cr ₹25.82 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories ₹6.1 Cr ₹2.02 Cr ₹1.18 Cr -₹1.88 Cr ₹2.14 Cr -₹6.09 Cr -₹4.5 Cr ₹2.38 Cr ₹55.62 Lakh -₹4.11 Cr -₹4.52 Cr -₹5.24 Cr
Employee Benefit Expense ₹6.24 Cr ₹5.53 Cr ₹5.71 Cr ₹5.31 Cr ₹5.52 Cr ₹5.44 Cr ₹5.13 Cr ₹5.48 Cr ₹5.88 Cr ₹5.77 Cr ₹5.23 Cr ₹5.25 Cr
Finance Costs ₹59.89 Lakh ₹78.2 Lakh ₹84.12 Lakh ₹56.22 Lakh ₹62.27 Lakh ₹73.25 Lakh ₹1.01 Cr ₹67.85 Lakh ₹1.87 Cr ₹64.66 Lakh ₹90.72 Lakh ₹95.65 Lakh
Depreciation & Amortisation ₹1.73 Cr ₹1.75 Cr ₹1.81 Cr ₹1.77 Cr ₹46.61 Lakh ₹2.17 Cr ₹2.57 Cr ₹1.74 Cr ₹1.77 Cr ₹1.76 Cr ₹1.8 Cr ₹1.68 Cr
Other Expenses ₹12.78 Cr ₹9.61 Cr ₹9.03 Cr ₹7.12 Cr ₹8.52 Cr ₹7.67 Cr ₹7.05 Cr ₹7.34 Cr ₹9.1 Cr ₹8.24 Cr ₹8.3 Cr ₹7.27 Cr
Total Expenses ₹52.88 Cr ₹40.94 Cr ₹39.83 Cr ₹36.75 Cr ₹28.18 Cr ₹37.81 Cr ₹39.88 Cr ₹39.04 Cr ₹41.83 Cr ₹41.03 Cr ₹39.22 Cr ₹35.73 Cr
Profit Before Exceptional Items & Tax ₹3.53 Cr ₹3.08 Cr ₹2.77 Cr ₹2.17 Cr ₹3.04 Cr ₹3.48 Cr ₹3.25 Cr ₹3.02 Cr ₹3.73 Cr ₹4.01 Cr ₹4 Cr ₹5.15 Cr
Exceptional Items ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹3.53 Cr ₹3.08 Cr ₹2.77 Cr ₹2.17 Cr ₹3.04 Cr ₹3.48 Cr ₹3.25 Cr ₹3.02 Cr ₹3.73 Cr ₹4.01 Cr ₹4 Cr ₹5.15 Cr
Total Tax Expense ₹55.73 Lakh ₹48.7 Lakh ₹56.2 Lakh ₹53.27 Lakh ₹62.66 Lakh ₹95.5 Lakh ₹98.51 Lakh ₹75.76 Lakh ₹62.2 Lakh ₹1.24 Cr ₹98.84 Lakh ₹73.63 Lakh
Net Profit ₹2.97 Cr ₹2.59 Cr ₹2.21 Cr ₹1.64 Cr ₹2.41 Cr ₹2.52 Cr ₹2.27 Cr ₹2.26 Cr ₹3.1 Cr ₹2.77 Cr ₹3.01 Cr ₹4.42 Cr
Other Comprehensive Income ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Total Comprehensive Income ₹2.97 Cr ₹2.59 Cr ₹2.21 Cr ₹1.64 Cr ₹2.41 Cr ₹2.52 Cr ₹2.27 Cr ₹2.26 Cr ₹3.1 Cr ₹2.77 Cr ₹3.01 Cr ₹4.42 Cr
EBITDA (computed) ₹5.85 Cr ₹5.61 Cr ₹5.42 Cr ₹4.5 Cr ₹4.13 Cr ₹6.38 Cr ₹6.84 Cr ₹5.44 Cr ₹7.37 Cr ₹6.42 Cr ₹6.7 Cr ₹7.79 Cr
Basic EPS ₹2.19 ₹1.91 ₹1.63 ₹1.21 ₹1.90 ₹1.98 ₹0.00 ₹1.78 ₹2.45 ₹2.19 ₹2.38 ₹3.49
Diluted EPS ₹2.19 ₹1.91 ₹1.63 ₹1.21 ₹1.90 ₹1.98 ₹0.00 ₹1.78 ₹2.45 ₹2.19 ₹2.38 ₹3.49
Latest 12 quarters shown of 16 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Medicamen Biotech Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Medicamen Biotech Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 40.46%, foreign institutional investors hold 0.10%, retail and other public shareholders hold 59.39% of Medicamen Biotech Limited. The company had 10,806 shareholders on record.

Promoters: 40.46%FII (Foreign Institutional): 0.10%Retail & Others: 59.39%
Mar 2026
QUARTER
40.46% Promoters
0.10% FII (Foreign Institutional)
59.39% Retail & Others
Promoter holding - history
Now 40.46% · Mar 2026High 44.83% · Sep 2021Low 40.46% · Apr 2025
39%40.8%42.5%44.3%46%Sep 2021Sep 2022Sep 2023Sep 2024Jun 2025Sep 2021: 44.83%Dec 2021: 43.60%Mar 2022: 43.60%Jun 2022: 43.60%Sep 2022: 43.21%Dec 2022: 43.21%Mar 2023: 43.21%Jun 2023: 43.21%Sep 2023: 43.21%Dec 2023: 43.21%Mar 2024: 43.21%Jun 2024: 42.99%Sep 2024: 42.99%Dec 2024: 42.99%Mar 2025: 43.16%Apr 2025: 40.46%Jun 2025: 40.46%Sep 2025: 40.46%Dec 2025: 40.46%Mar 2026: 40.46%44.83%40.46%40.46%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Apr 2025Mar 2025
Promoters40.46%40.46%40.46%40.46%40.46%43.16%
Public59.54%59.54%59.54%59.54%59.54%56.84%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Promoters40.46%43.16%43.21%43.21%43.60%
Public59.54%56.84%56.79%56.79%56.40%
Promoter change (YoY, %pts)-2.70-0.05+0.00-0.39-

Board & Governance of Medicamen Biotech Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Medicamen Biotech Limited has 12 directors - 7 independent and 1 executive. The board is chaired by Rahul Bishnoi.

DirectorPositionOn board sinceListed boards
Arun Kumar Non-Executive - Independent Director 2016-02-27 2
Ashwani Kumar Sharma Executive Director 2025-08-12 2
Harish Pande Non-Executive - Independent Director 2015-12-31 3
Sanjay Bansal Non-Executive - Non Independent Director 2016-02-27 2
Suresh Kumar Singh Non-Executive - Non Independent Director 2015-12-31 2
Sumita Dwivedi Non-Executive - Independent Director 2018-11-13 2
Sangeeta Bishnoi Non-Executive - Independent Director 2019-02-11 2
Vimal Kumar Shrawat Non-Executive - Non Independent Director 2019-02-11 2
Ravi Kumar Bansal Non-Executive - Independent Director 2019-05-30 2
Rahul Bishnoi Non-Executive - Non Independent Director · Chairperson 2015-12-31 2
Shaival Saurabh Non-Executive - Independent Director 2025-08-12 2
Sham Goel Non-Executive - Independent Director 2025-08-12 2
Board Committees
CommitteeMembers
Audit Committee Sham Goel (Chairperson), Ashwani Kumar Sharma, Sumita Dwivedi, Harish Pande (Chairperson), Arun Kumar
Nomination and remuneration committee Sham Goel (Chairperson), Ashwani Kumar Sharma, Sumita Dwivedi, Harish Pande (Chairperson), Arun Kumar
Stakeholders Relationship Committee Sham Goel (Chairperson), Ashwani Kumar Sharma, Sumita Dwivedi, Harish Pande (Chairperson), Arun Kumar
Risk Management Committee Sham Goel (Chairperson), Ashwani Kumar Sharma, Sumita Dwivedi, Harish Pande (Chairperson), Arun Kumar
Corporate Social Responsibility Committee Sham Goel (Chairperson), Sanjay Bansal, Suresh Kumar Singh, Harish Pande (Chairperson)

Group Structure of Medicamen Biotech Limited

Medicamen Biotech Limited has 1 subsidiary company. This group structure data is as of FY 2024. The corporate group structure reflects Medicamen Biotech Limited's business expansion strategy and organizational complexity.

1
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Medicamen Life Sciences Private Limited U24290DL2022PTC403121 -

Showing major subsidiaries. Total: 1.

Charges & Borrowings of Medicamen Biotech Limited

Open charges
₹66.43 Cr
Satisfied charges
₹52.09 Cr
Breakdown by lending institutions
Others₹46.08 Cr
Citi Bank N.A.₹20.00 Cr
Hdfc Bank Limited₹0.35 Cr
Latest charge details
DateLenderAmountStatus
06 May 2026 Others ₹52.83 Lakh Open
28 Mar 2025 Others ₹9 Cr Open
21 Mar 2025 Others ₹1.17 Cr Open
10 May 2023 Hdfc Bank Limited ₹35 Lakh Open
19 Mar 2021 Citi Bank N.A. ₹20 Cr Open

Total charge records: 11 View all charges

Employees and EPFO Compliance at Medicamen Biotech Limited

Medicamen Biotech Limited has a workforce of 314 employees as of Feb 27, 2025.

Employee count
314
Active EPFO establishments
3
Employee growth
-22.47%
Premium access

Employee and EPFO history for Medicamen Biotech Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Medicamen Biotech Limited

Premium access

GST registrations and filing compliance for Medicamen Biotech Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Medicamen Biotech Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Medicamen Biotech Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Medicamen Biotech Limited

Premium access

MSME payment history for Medicamen Biotech Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Medicamen Biotech Limited

Premium access

Corporate group structure for Medicamen Biotech Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Medicamen Biotech Limited

Premium access

MCA filings and documents for Medicamen Biotech Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Medicamen Biotech Limited

Charges
06 May 2026
A charge with Others amounted to Rs. 0.53 Cr with Charge ID 101322836 was registered on 06 May 2026.
Activity
26 Sep 2025
Medicamen Biotech Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records.
Directors
12 Aug 2025
Shaival Saurabh was appointed as a Director on 12 Aug 2025 & has been associated with this company since 1 year 1 month.
Directors
12 Aug 2025
Sham Goel was appointed as a Director on 12 Aug 2025 & has been associated with this company since 1 year 1 month.
Charges
30 Jul 2025
A charge with Others of Rs. 9.00 Cr registered on 28 Mar 2025 with Charge ID 101091431 was modified on 30 Jul 2025.
Charges
23 Jun 2025
A charge with Citi Bank N.A. of Rs. 20.00 Cr registered on 19 Mar 2021 with Charge ID 100449354 was modified on 23 Jun 2025.

Recent News on Medicamen Biotech Limited

Frequently Asked Questions about Medicamen Biotech Limited

Medicamen Biotech Limited is an active public limited company in the pharma sector based in New Delhi, Delhi, India. It was incorporated on 22 December 1993 (33+ years old) and is registered under CIN L74899DL1993PLC056594. Listed on BSE: 531146 and NSE: MEDICAMEQ. The company has 314 employees.

Medicamen Biotech Limited reported revenue of ₹197.77 Cr for FY 2026 (up 21.67% YoY) based on consolidated NSE filings.

The current directors of Medicamen Biotech Limited are:

The primary industry of Medicamen Biotech Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Medicamen Biotech Limited is listed on both BSE (code: 531146) and NSE (symbol: MEDICAMEQ).

Medicamen Biotech Limited can be reached at the registered office: 1506 Chiranjiv Tower 43 Nehru Place, New Delhi, Delhi, India – 110019, or through the website medicamen.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available